Elicio Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Elicio Therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 28.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | N/A | -42 | -42 | 2 |
| 12/31/2025 | N/A | N/A | -41 | -41 | 3 |
| 12/31/2024 | N/A | N/A | -37 | -37 | 3 |
| 9/30/2024 | N/A | -47 | -38 | -38 | N/A |
| 6/30/2024 | N/A | -39 | -36 | -36 | N/A |
| 3/31/2024 | N/A | -39 | -37 | -37 | N/A |
| 12/31/2023 | N/A | -35 | -33 | -33 | N/A |
| 9/30/2023 | N/A | -33 | -30 | -30 | N/A |
| 6/30/2023 | N/A | -29 | -30 | -30 | N/A |
| 3/31/2023 | N/A | -29 | -25 | -25 | N/A |
| 12/31/2022 | N/A | -28 | -23 | -22 | N/A |
| 9/30/2022 | N/A | -28 | -22 | -21 | N/A |
| 3/31/2022 | N/A | -27 | -24 | -23 | N/A |
| 12/31/2021 | N/A | -26 | -24 | -24 | N/A |
| 3/31/2021 | N/A | -19 | -20 | -20 | N/A |
| 12/31/2020 | N/A | -16 | -17 | -17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ELTX's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if ELTX's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if ELTX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if ELTX's revenue is forecast to grow faster than the US market.
High Growth Revenue: ELTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ELTX's Return on Equity is forecast to be high in 3 years time